Keep up to date with insights into hot topics and the biggest events
in the UC calendar
Professor Stefan Schreiber from the University Hospital Schleswig-Holstein, Germany presents a post hoc analysis of the SELECTION trial finding that treatment with filgotinib 200 mg resulted in a higher proportion of patients achieving a combined endpoint of clinical, endoscopic, biological and health-related quality of life outcomes versus placebo (post hoc analysis) at Week 10 in Biologic-Naïve patients (p<0.001) and at Week 58 (p=0.002).
Dr Nick Powell dives into the role of the JAK-STAT pathway in inflammation.
GB-UC-JY-202303-00006 | Date of preparation: October 2023
Adverse events should be reported.
For Great Britain, reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 0800 072 7878.
Adverse events should be reported.
For Northern Ireland, reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 0800 072 7878.
Adverse events should be reported.
For the Republic of Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971.
Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 00800 7878 1345.
Jyseleca, Galapagos and the Galapagos logo are registered trademarks of Galapagos NV.
GB-IBD-FIL-202211-00008
Date of preparation: November 2023
Contact Us
Galapagos Biotech Ltd
148 Belmont Rd, Uxbridge UB8 1QS
medicalinfo@glpg.com
Jyseleca, Galapagos and the Galapagos logo are registered trademarks of Galapagos NV.
GB-IBD-FIL-202211-00008
Date of preparation: November 2023
Contact Us
Galapagos Biotech Ltd
148 Belmont Rd, Uxbridge UB8 1QS
medicalinfo@glpg.com
© 2023 Galapagos NV. All rights reserved.
This link will take you away from the Galapagos website and you will be re-directed to a non-Galapagos website. Galapagos does not accept liability for sites controlled by third-parties.
